EMA CHMP May 2026: New Medicine Opinions
Decision brief
Answer first · skim in under a minute
The EMA's CHMP has backed four new medicines during its May meeting, marking significant advancements in clinical trials. This analysis explores the implications for investors and pharma teams.
EMA’s CHMP May 2026 meeting did not stop at four endorsements: the committee recommended eight medicines for approval on 18–21 May 2026, including Jascayd, Vijoice, Boey and Etcamah, while also extending indications for 13 authorised products and refusing one diagnostic.
Contents9 sections
Key Takeaways
- CHMP’s 18–21 May 2026 session produced eight positive opinions on new medicines (2026 cumulative: 36), per EMA meeting highlights published 22 May 2026.
- Headline new actives include nerandomilast (Jascayd), alpelisib for PROS (Vijoice, orphan), trenibotulinumtoxinE (Boey), and camizestrant (Etcamah).
- Vislyfa (ranibizumab) biosimilar and three hybrid/generic products also received positive opinions; Deqtynet received a negative opinion.
- Opinions remain pending European Commission decision—not final marketing authorisations.
What did CHMP actually decide in May 2026?
EMA’s official highlights correct thinner secondary summaries that claimed only four new medicines.
According to Meeting highlights from the CHMP 18–21 May 2026, the committee recommended eight medicines for approval and recommended extensions of therapeutic indication for 13 already authorised medicines. Statistics on the same page list one negative opinion on a new medicine and two withdrawn initial applications in the month.
Among new actives, Jascayd (nerandomilast) from Boehringer Ingelheim was recommended for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. Vijoice (alpelisib) from Novartis received a recommended conditional marketing authorisation for severe or life-threatening PIK3CA-related overgrowth spectrum in patients aged 2 years and older, with orphan designation.
Which oncology and aesthetics opinions change competitive maps?
Etcamah (camizestrant) from AstraZeneca received a positive opinion for adults with ER-positive, HER2-negative locally advanced or metastatic breast cancer with ESR1 mutation, in combination with a CDK4/6 inhibitor after first-line endocrine therapy without progression—an oral SERD entry that competitors must model into EU sequencing.
EMA’s medicine page for Etcamah records the 21 May 2026 CHMP positive opinion and pending EC decision status. Boey (trenibotulinumtoxinE) from AbbVie was recommended for temporary improvement of moderate to severe glabellar lines with important psychological impact in adults, expanding aesthetic neurotoxin competition beyond classic onabotulinumtoxinA analogues.
For pulmonary fibrosis franchises, the Jascayd EPAR opinion page likewise timestamps the 21 May 2026 positive opinion for IPF and PPF.
How should biosimilar and hybrid approvals be read?
Not every “new medicine” opinion is a first-in-class active.
Vislyfa (ranibizumab) from Lupin received a biosimilar positive opinion across wet AMD and other retinal indications. Hybrid applications for Ablymico and Liraglutide STADA (both liraglutide) plus Colchicine AGEPHA Pharma add volume competition in weight management, type 2 diabetes, and secondary cardiovascular prevention. Those products matter for pricing and tender strategy even when they do not change molecular novelty narratives.
Related NovaPharma EU coverage includes CHMP drug approvals analysis and FDA versus EMA camizestrant controversy.
What else moved besides the eight new medicines?
CHMP recommended indication extensions for Braftovi, Enhertu, Erbitux, Fasenra, Hetronifly, Iclusig, Keytruda, Maviret, Padcev, Palynziq, Sogroya, Tepkinly and Trodelvy—eighteen positive extension opinions counting the monthly statistics graphic’s cumulative framing.
The committee also recommended not granting authorisation for Deqtynet (copper (64Cu) oxodotreotide), a PET diagnostic for well-differentiated neuroendocrine tumours. Applications for Orblid (bevacizumab) and Veblocema (infliximab) were withdrawn. Separately, CHMP backed an oral Wegovy (semaglutide) tablet extension for weight management—the first oral GLP-1 for that use in the EU pathway described in the highlights.
What remains unproven until Commission decisions?
CHMP opinions are recommendations. European Commission marketing authorisations, final product information, and national pricing/reimbursement outcomes are still ahead.
Do not treat “CHMP backed” as “EU launched.” Track each medicine page for the shift from “pending EC decision” to authorised status before updating launch models or competitive share forecasts. Also watch national HTA timelines, because reimbursement can lag the Commission decision by many months in major EU markets.
Related NovaPharma coverage
- CHMP Approves New Medicines: Key Decisions and Implications
- Lilly hematology portfolio at 2026 EHA
- ESMO Asia oncology advances
Frequently Asked Questions
How many new medicines did CHMP recommend in May 2026?
EMA’s meeting highlights state that CHMP recommended eight medicines for approval at its 18–21 May 2026 meeting: three new non-orphan medicines, one orphan medicine, one biosimilar, and three generic, hybrid or informed-consent medicines, bringing the 2026 cumulative total to 36 positive opinions on new medicines.
Which notable new active substances received positive opinions?
Jascayd (nerandomilast) for idiopathic or progressive pulmonary fibrosis, Vijoice (alpelisib) for severe PIK3CA-related overgrowth spectrum with orphan designation, Boey (trenibotulinumtoxinE) for glabellar lines, and Etcamah (camizestrant) for ESR1-mutated ER-positive, HER2-negative advanced breast cancer.
Are CHMP positive opinions the same as EU marketing authorisation?
No. A CHMP positive opinion is a recommendation; European Commission marketing authorisation is still required. EMA medicine pages for Jascayd, Etcamah and peers listed the products as pending EC decision after the May 2026 opinions.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
